After months of conflicting results from smaller trials, the eagerly anticipated RECOVERY trial has found that the IL-6 inhibitor tocilizumab does in fact improve outcomes in patients hospitalised with COVID-19. “Previous trials of tocilizumab had shown mixed results, and it was unclear which patients might benefit from the treatment,” said Prof Peter Horby, of the ...
Tocilizumab offers clear benefit for hospitalised COVID-19 patients: RECOVERY
By Dave Levitan
24 Feb 2021